Patent 10166225 was granted and assigned to Exelixis Ltd on January, 2019 by the United States Patent and Trademark Office.
This invention is directed to the treatment of osteoporosis using N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide.